Skip to main content

How we treat

This Journal of Hematology & Oncology series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders.

All submissions to this series need to be pre-approved. Prospective authors should contact the Journal Development Manager for pre-approval with the outline of their paper, the lead author name, and institution.

The deadline for submissions is 31 October 2021.

Manuscripts sponsored by pharmaceutical companies will not be considered.

© xixinxing / Fotolia.

  1. Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an ex...

    Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell and Erel Joffe

    Citation: Journal of Hematology & Oncology 2021 14:5

    Content type: Review

    Published on: